The COVID-19 Pandemic will require multiple strategies beyond vaccination in order to reduce mortality and help countries to safely reopen. This conference will focus on general treatments and innovative protocols in use for different parts of the world.
Dr Shankara Chetty – South Africa
Dr Fernando Valerio – Honduras
Dr Hamid Merchant – UK
Dr James Lundeen – USA
Dr Christopher Ring – UK
Dr Carlette Norwood-Williams – USA
John Ables – USA
Don Turner (Neosinus) – USA
Most viewed video…
Geert Vanden Bossche PhD, is an internationally recognised vaccine developer having worked as the head of the Vaccine Development Office at the German Centre for Infection Research. Coordinated Global Alliance for Vaccines and Immunisation’s Ebola Vaccine Program and contributed to the implementation of an integrated vaccine work plan in collaboration with Global Health Partners (WHO, Bill & Melinda Gates Foundation, CDC, UNICEF), regulators (FDA) and vaccine manufacturers to enable timely deployment or stockpiling of Ebola vaccine candidates.
Highlighting the principle of using a prophylactic vaccine in the midst of a pandemic. Likely to create more more viral variants in the process.
Sharing his perspective on mass vaccination in COVID-19.
Macrophage Activation Syndrome in COVID-19 was being discounted at the time when I heard it first. It remained unexplained for over a year and finally made sense when I reflected on the consistent elevation of ferritin in most severe cases.
The delayed interferon response to SARS-COV2 which occurs in people without prior coronavirus (not just COVID-19) exposure, causes an accumulation of immature monocytes in lung tissue.
Once the immune system has been activated to target ACE-2 (autoimmune response), autoantibodies will then cause widespread monocyte activation, primarily in the lungs.
This concept is important to understand as we are likely to see different disease presentation, eg, kidney and heart disease, in those who have elevated serum ACE-2 and were previously vaccinated.
In unclear cases, we can measure the ferritin and if 5 to 10 times above normal, consider steroids to treat possible Macrophage Activation Syndrome.
McMillan Research does not currently have real world evidence data regarding all aspects of autoimmunity in COVID-19. The theory of autoimmunity in COVID-19 could form the basis for clinical investigation and medical monitoring. There are many challenges associated with clinical trials, especially clinical human trials. A clinical trial study requires a comprehensive development plan, and may use clinical biostatistics. A centre for clinical research focused on long COVID, could potentially provide much needed solutions.